Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29978848 | 1.00 | ALDH1A1 (0.71) | ALDH1A1CYP2C9CYP2C19MAPTLMNA | |
| SCHEMBL21972975 | 0.87 | ALDH1A1 (0.64) | ALDH1A1CYP2C9CYP2C19MAPTLMNA | |
| SCHEMBL29978554 | 0.87 | ALDH1A1 (0.64) | ALDH1A1CYP2C9CYP2C19MAPTLMNA | |
| SCHEMBL21972358 | 0.87 | TP53 (0.67) | ALDH1A1CYP2C9CYP2C19MAPTLMNA | |
| SCHEMBL21972974 | 0.86 | MAPT (0.78) | ALDH1A1CYP2C9CYP2C19MAPTLMNA | |
| SCHEMBL31411550 | 0.85 | LMNA (0.58) | ALDH1A1CYP2C9CYP2C19MAPTLMNA | |
| SCHEMBL31411689 | 0.84 | ALDH1A1 (0.56) | ALDH1A1CYP2C9CYP2C19MAPTLMNA | |
| SCHEMBL29227219 | 0.83 | ALDH1A1 (0.59) | ALDH1A1CYP2C9CYP2C19MAPTLMNA | |
| SCHEMBL31411570 | 0.83 | ALDH1A1 (0.58) | ALDH1A1CYP2C9CYP2C19MAPTLMNA | |
| SCHEMBL10022667 | 0.83 | LMNA (0.68) | ALDH1A1CYP2C9CYP2C19LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118159535-A | Small molecule STING antagonists | 库拉德夫制药私人有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| CN-115151304-A | Small molecule interferon gene stimulating factor (STING) antagonists | 库拉德夫制药私人有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021161230-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | ALDH1A1 2654/4885CYP2C9 4363/4885CYP2C19 4663/4885 |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | ALDH1A1 3672/4885CYP2C9 3960/4885CYP2C19 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.